Pain Processing in Inflammatory and Non-Inflammatory Chronic Pain Syndromes

Recruiting in Palo Alto (17 mi)

Overseen by Roland Staud, M.D.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: University of Florida

No Placebo Group

Trial Summary

What is the purpose of this trial?

Fibromyalgia (FM) is a chronic musculoskeletal pain disorder that afflicts up to 4% of the general population. The evaluation of pain mechanisms in FM has shown predominant central abnormalities and therefore has been designated as nociplastic pain syndrome. Rheumatoid arthritis (RA) is characterized by polyarthritis and pain from inflamed tissues, consistent with nociceptive pain. FM and RA patients may utilize overlapping pain mechanisms resulting in nociceptive and nociplastic pain.

Research Team

Roland Staud, M.D.

Principal Investigator

University of Florida

Eligibility Criteria

Inclusion Criteria

Fulfills the 1990 and 2011 American College of Rheumatology Criteria for FM

Fulfills the 2010 ACR-EULAR classification criteria for RA

Healthy volunteers: No significant pain/fatigue/depression/anxiety.

Treatment Details

Interventions

• Pain Processing Evaluation (Behavioural Intervention)

Who Is Running the Clinical Trial?

University of Florida

Lead Sponsor

Trials

1,428

Recruited

987,000+

Dr. Stephen J. Motew

University of Florida

Chief Executive Officer since 2024

MD cum laude from the University of Illinois at Chicago School of Medicine, Master's in Healthcare Administration from the University of North Carolina at Chapel Hill

Dr. Timothy E. Morey

University of Florida

Chief Medical Officer since 2023

MD and Bachelor's from the University of Florida